On April 4, 2023, NanoViricides announced a licensing agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India, that grants Karveer the right to commercialize NV-CoV-2 and NV-CoV-2-R in India. Karveer has begun clinical development and evaluation of those two drugs and has obtained regulatory permissions to conduct clinical evaluation of them in India. We anticipate the clinical trials getting underway in India in the near future.
It’s been a long road for NanoViricides as the company has been developing various preclinical assets for more than a decade. However, the company is now ready to move its first development candidate into clinical testing and we look forward to the results of those studies later this year.
Market Data 
Markets 
AI
